Marrone Bio Innovations Stock News

RALEIGH, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, announced today a tran

Marrone Bio Innovations Inc. (NASDAQ:MBII) shares, rose in value on Friday, 02/18/22, with the stock price down by -2.92% to the previous days close as strong demand from buyers drove the stock to $0.65. Actively observing the price movement in the last trading, the stock closed the session at $0.67, falling within a range of Marrone Bio Innovations Inc. (NASDAQ: MBII) Stock Seems Like A Good Option Read More »

GAINERS: Icanic Brands (OTC: ICNAF ) shares closed up 9.51% at $0.18 Neptune Wellness Solns (NASDAQ: NEPT ) shares closed up 6.20% at $0.44 Cann Gr (OTC: CNGGF ) shares closed up 3.86% at $0.21 LOSERS: Rhinomed (OTC: RHNMF ) shares closed down -14.09% at $0.19 Cannabix Technologies (OTC: BLOZF ) shares closed down -13.85% at $0.56 Item 9 Labs (OTC: INLB ) shares closed down -13.21% at $0.92 Marrone Bio Innovations (NASDAQ: MBII ) shares closed down -8.23% at $0.64 Greenlane Hldgs (NASDAQ: GNLN ) shares closed down -7.96% at $0.76 Full story available on Benzinga.com

Announces Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results Announces Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.

Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.

RALEIGH, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) has expanded its existing inventory line of credit to support the company’s expectations for growth in

RALEIGH, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII ) has expanded its existing inventory line of credit to support the company''s expectations for growth in sales and manufacturing capacity. Under an amended agreement with LSQ Funding Group, L.C., the company can access a maximum of $4.5 million to finance inventory needs, up from $3 million under a prior agreement. "The increase in the line of credit for inventory provides us with greater flexibility to support the company''s commercial expansion in the near future," said Chief Executive Officer Kevin Helash. "This is particularly critical as we enter the peak selling season in our North American markets to ensure we have the ability to provide customers with ready access to our products when they need them." About Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII ) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition.

Supports Growth Plans in European and Latin American markets Supports Growth Plans in European and Latin American markets

Freeport-McMoRan Inc. (NYSE:FCX) with the stream of 2.47% also noticed, India Marrone Bio Innovations, Inc. (NASDAQ:MBII) encountered a rapid change of -2.75% in the last hour of Thursdays trading session. The post An Eye on Data: Freeport-McMoRan Inc. (NYSE:FCX), Marrone Bio Innovations, Inc. (NASDAQ:MBII) appeared first on Stocks Equity .

DAVIS, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- During November and December 2021, certain warrant holders in Marrone Bio Innovations, Inc. (NASDAQ: MBII) completed the exercise of the fifth and f

DAVIS, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- During November and December 2021, certain warrant holders in Marrone Bio Innovations, Inc. (NASDAQ: MBII) completed the exercise of the fifth and final tranche of warrants, generating a total of $3.5 million in cash during the fourth quarter of 2021 and increasing the companys outstanding shares by 4.7 million. With these exercises, and the December 15, 2021, expiration of the substantial majority of the companys other unexercised warrants, the companys material warrant overhang has been eliminated.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) has earned a consensus rating of Buy from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued []

AT&T Inc. (NYSE:T) with the stream of -0.44% also noticed, India Marrone Bio Innovations, Inc. (NASDAQ:MBII) encountered a rapid change of -3.40% in the last hour of Fridays trading session. The post ATR Oversold/Overbought Signals to Track: AT&T Inc. (NYSE:T), Marrone Bio Innovations, Inc. (NASDAQ:MBII) appeared first on Stocks Equity .

Wall Street brokerages forecast that Marrone Bio Innovations, Inc. (NASDAQ:MBII) will announce sales of $9.86 million for the current quarter, Zacks reports. Two analysts have issued estimates for Marrone Bio Innovations earnings, with the highest sales estimate coming in at $10.01 million and the lowest estimate coming in at $9.70 million. Marrone Bio Innovations posted []